Dr. Husain discusses how updated MARIPOSA and FLAURA-2 data highlight the growing role of combination regimens in improving both systemic and CNS outcomes for patients with EGFR-mutant NSCLC.
Evolving Treatment Approaches in EGFR- Mutated NSCLC: First-Line Therapies and AE Management
Dr. Husain discusses how selecting between FLAURA-2, MARIPOSA, and other frontline regimens requires balancing efficacy, safety, and sequencing considerations to deliver the most personalized care in EGFR-mutant NSCLC.
Dr. Husain discusses how anticipating resistance mechanisms and tailoring post-progression strategies based on initial therapy are key to optimizing sequencing in EGFR-mutant NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Adjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma
2
Cryoablation Regimen Receives FDA Marketing Authorization for Breast Cancer
3
Salvage Nodal Radiation Shows Tolerability, Low Toxicity in Prostate Cancer
4
Tumor Size Determines Treatment Modality in Uveal Melanoma
5
